

patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH19–013, Advancing Infectious Disease Detection and Response in Liberia.

Date: April 30, 2019.

Time: 9:00 a.m.–2:00 p.m., EDT.

Place: Teleconference.

Agenda: To review and evaluate grant applications.

For Further Information Contact: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, GA 30329–4027, (404) 639–4796; HShoob@cdc.gov.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2019–04825 Filed 3–14–19; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis (ACET)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting of the Advisory Council for the Elimination of Tuberculosis Meeting (ACET). This meeting is open to the public, limited only by the space available. The meeting room will accommodate up to 60 people. The public is also welcome to listen to the meeting by telephone, limited only by the number of ports available (100). Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is Monday, April 15, 2019. Persons who desire to make an

oral statement, may request it at the time of the public comment period on April 16, 2019 at 3:20 p.m. EDT.

DATES: The meeting will be held on April 16, 2019, 10:00 a.m. to 3:30 p.m., EDT.

ADDRESSES: 8 Corporate Blvd., Building 8, Conference Rooms 1A and 1B, Atlanta, Georgia 30329 and Web conference: 1–877–927–1433 and participant passcode: 12016435 and <https://adobeconnect.cdc.gov/r5p8l2tytpq/>.

FOR FURTHER INFORMATION CONTACT:

Margie Scott-Cseh, Committee Management Specialist, CDC, 1600 Clifton Road NE, Mailstop: E–07, Atlanta, Georgia 30329–4018, telephone (404) 639–8317; zkr7@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: This Council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

Matters to be considered: The agenda will include discussions on (1) Overview of the “Digital Bridge”; (2) Overview of tuberculosis care for migrant detainees; (3) Overview of infrastructure and mechanisms to develop, update, and maintain HIV guidelines; and (4) Update from ACET workgroups. Agenda items are subject to change as priorities dictate.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2019–04822 Filed 3–14–19; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)

CK19–002, Quantifying Contact Rates and Mixing Patterns in Workers in Non-Healthcare Work Settings in the United States and CK19–004, Study to Assess the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease (CJD).

Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP); CK19–002, Quantifying Contact Rates and Mixing Patterns in Workers in Non-Healthcare Work Settings in the United States and CK19–004, Study to Assess the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease (CJD); May 7, 2019; 10:00 a.m.–5:00 p.m., (EDT) which was published in the **Federal Register** on December 26, 2018, Volume 83, Number 246, pages 66270.

The meeting is being amended to add CK17–005SUPP, Vector-Borne Disease Regional Centers of Excellence. The meeting is closed to the public.

Contact: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60, Atlanta, Georgia 30333, (404) 718–8833, gca5@cdc.gov.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2019–04823 Filed 3–14–19; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH19–003, Advancing Infectious Disease Detection and Response in Senegal; GH19–006, Advancing Infectious Disease Detection and Response in Indonesia; GH19–008, Advancing Infectious Disease Detection and Response in Uganda; GH19–009, Advancing Infectious Disease Detection and Response in Vietnam; GH19–010, Advancing Disease Detection and Response in Nigeria; and GH19–015, Strengthening National Capacity for Malaria Operations Research in Malawi.

Date: April 24, 2019.

Time: 9:00 a.m.–2:00 p.m., EDT.

Place: Teleconference.

Agenda: To review and evaluate grant applications.

FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, GA 30329–4027, (404) 639–4796; HShoob@cdc.gov.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2019–04848 Filed 3–14–19; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number CDC–2019–0015, NIOSH–153–E]

Request for the Technical Review of 10 Draft Skin Notation Assignments and Skin Notation Profiles

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Request for information and comment.

SUMMARY: The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of 10 draft skin notation profile documents now available for public comment entitled:

Skin notation profile: Cyclohexanol

Skin notation profile: Cyclohexanone

Skin notation profile: Cyclonite

Skin notation profile: Diacetyl and 2,3-Pentanedione

Skin notation profile:

Diethylenetriamine

Skin notation profile: beta-Chloroprene

Skin notation profile: Chlorodiphenyl 42% Chlorine

Skin notation profile: Chlorodiphenyl 54% Chlorine

Skin notation profile: Dioxane

Skin notation profile: 2,4-Toluene

diisocyanate, 2,6-Toluene

diisocyanate, and the mixture of 2,4- and 2,6-Toluene diisocyanate

To view the notice and related

materials, visit [https://](https://www.regulations.gov)

www.regulations.gov and enter CDC–2019–0015 in the search field and click “Search.”

DATES: Electronic or written comments must be received by May 14, 2019.

ADDRESSES: You may submit comments, identified by CDC–2019–0015 and docket number NIOSH–153–E, by any of the following methods:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments.

- **Mail:** National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998.

Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2019–0015; NIOSH–153–E]. All relevant comments received will be

posted without change to <https://www.regulations.gov>, including any personal information provided. All electronic comments should be formatted as Microsoft Word. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226–1998.

FOR FURTHER INFORMATION CONTACT:

Naomi Hudson, NIOSH/EID, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C32, Cincinnati, OH 45226. Telephone: (513) 533–8388 (not a toll free number).

SUPPLEMENTARY INFORMATION: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) is conducting a public review of the draft skin notations and support technical documents, entitled Skin Notations Profiles, for 10 chemicals. NIOSH is requesting technical reviews of the draft Skin Notation Profiles.

Background: In 2009, NIOSH published Current Intelligence Bulletin (CIB) 61—A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009–147; <http://www.cdc.gov/niosh/docs/2009-147/pdfs/2009-147.pdf>]. The CIB presents a strategic framework that is a form of hazard identification designed to do the following:

1. Ensure that the assigned skin notations reflect the contemporary state of scientific knowledge.
2. Provide transparency behind the assignment process.
3. Communicate the hazards of chemical exposures of the skin.
4. Meet the needs of health professionals, employers, and other interested parties in protecting workers from chemical contact with the skin.

This strategy involves the assignment of multiple skin notations for distinguishing systemic (SYS), direct (DIR), and sensitizing (SEN) effects caused by exposure of skin (SK) to chemicals.

Information Needs: To facilitate the review of these documents, NIOSH requests that the following questions be taken into consideration:

1. Does this document clearly outline the systemic health hazards associated with exposures of the skin to the chemical? If not, what specific information is missing from the document?
2. If the SYS or SYS (FATAL) notations are assigned, are the rationale